Sino Biopharmaceutical Gains Approval for Innovative Tulobuterol Patch

Sino Biopharmaceutical ( (HK:1177) ) has issued an announcement.

Sino Biopharmaceutical Limited has received approval from the National Medical Products Administration of China to market the first domestically produced tulobuterol patch for obstructive airway diseases. This innovative transdermal patch offers a more effective and convenient solution for asthma and other related conditions, particularly benefiting children due to its easy administration. The introduction of this patch not only breaks the monopoly of imported drugs but also addresses the supply challenges of asthma medication for children in China. This approval strengthens Sino Biopharmaceutical’s position in the market and supports its strategy to expand and enrich its product pipeline.

More about Sino Biopharmaceutical

Sino Biopharmaceutical Limited is a leading enterprise in the transdermal formulations industry in China, with a diverse product pipeline including patches for analgesia, Parkinson’s disease, insomnia, and other areas. The company has successfully marketed products such as Flurbiprofen Cataplasms, Lidocaine Cataplasms, and Rivastigmine Transdermal Patch, demonstrating its commitment to health technology innovation.

YTD Price Performance: -5.13%

Average Trading Volume: 2,288

Technical Sentiment Consensus Rating: Strong Buy

Current Market Cap: $6.9B

For an in-depth examination of 1177 stock, go to TipRanks’ Stock Analysis page.